Anticoagulants in Pregnancy: Heparin, Warfarin and Neonatal Bleeding Risk

Introduction: Anticoagulation in Pregnancy and Neonatal Safety

Thromboembolic disease complicates approximately 1-2 per 1000 pregnancies, with pregnancy itself representing a hypercoagulable state due to increased clotting factor concentrations, decreased protein S activity, and venous stasis from uterine compression. Additionally, women with mechanical heart valves, antiphospholipid syndrome, inherited thrombophilias, and recurrent pregnancy loss frequently require anticoagulation throughout pregnancy. The choice of anticoagulant has profound implications for neonatal safety.

This guide reviews the placental transfer characteristics, fetal effects, and neonatal bleeding risks of major anticoagulant classes, with specific attention to the management of warfarin-exposed neonates and practical guidance for Indian clinical settings. FOGSI, ACOG, RCOG, and the American Heart Association guidelines inform the recommendations presented.

Anticoagulant Pharmacology in Pregnancy

Placental Transfer Characteristics

The placental transfer of anticoagulants determines their fetal and neonatal impact. This is the key pharmacological consideration governing drug selection in pregnancy.

Anticoagulant	Molecular Weight	Placental Transfer	Fetal/Neonatal Effect
Unfractionated heparin (UFH)	3,000-30,000 Da	Does not cross	None (safe)
LMWH (enoxaparin)	3,500-6,500 Da	Does not cross	None (safe)
Warfarin	308 Da	Crosses freely	Embryopathy, hemorrhage
Rivaroxaban	436 Da	Crosses	Embryotoxicity (animal data)
Fondaparinux	1,728 Da	Minimal (10%)	Limited data; minimal effect

Why Heparins Are Safe: The Placental Barrier

Both UFH and LMWH are too large and too negatively charged to cross the placental barrier. UFH (average MW 15,000 Da) and LMWH (average MW 4,500 Da) exceed the 500 Da threshold for free placental diffusion. Their strong negative charge further repels them from the negatively charged placental membrane. Multiple studies, including cord blood anti-Xa activity measurements, confirm negligible fetal exposure. This makes heparins the anticoagulant of choice throughout pregnancy.

Warfarin: Fetal and Neonatal Risks

Warfarin Embryopathy (First Trimester)

Warfarin exposure between weeks 6-12 of gestation causes the characteristic warfarin embryopathy syndrome in 5-10% of exposed fetuses. This includes nasal hypoplasia (underdeveloped nasal bridge due to abnormal cartilage calcification), stippled epiphyses (punctate calcifications in long bone epiphyses and vertebral bodies visible on X-ray), limb shortening (chondrodysplasia punctata pattern), and occasional eye abnormalities (optic atrophy). The mechanism involves inhibition of vitamin K-dependent matrix Gla protein and osteocalcin, which are essential for normal cartilage and bone development.

CNS Abnormalities (Second and Third Trimester)

Second and third trimester warfarin exposure carries a 1-2% risk of CNS abnormalities, primarily resulting from fetal intracranial hemorrhage. Microcephaly, cerebellar vermis hypoplasia, corpus callosum agenesis, and Dandy-Walker malformation have been reported. These devastating complications result from the fetal brain's vulnerability to hemorrhagic injury compounded by the anticoagulant effect of warfarin in a fetus with an immature coagulation system.

Neonatal Hemorrhagic Risk

Neonates born to mothers on warfarin at the time of delivery face significant bleeding risk. Warfarin's half-life in the neonate is prolonged (36-42 hours vs 25-60 hours in adults) due to immature hepatic metabolism. The anticoagulant effect may persist for 5-7 days after delivery. The elevated INR increases risk of intracranial hemorrhage, cephalohematoma extension, gastrointestinal bleeding, and bleeding from procedural sites. For this reason, warfarin must be switched to heparin by 36 weeks gestation.

Management Strategies for Pregnant Women Requiring Anticoagulation

Strategy 1: LMWH Throughout Pregnancy

This is the safest strategy for the fetus and is recommended for most indications. Enoxaparin is dosed at 1 mg/kg twice daily for therapeutic anticoagulation or 40 mg daily for prophylaxis, with anti-Xa level monitoring. This approach is standard for venous thromboembolism treatment, antiphospholipid syndrome, and most thrombophilias.

Strategy 2: LMWH First Trimester, Warfarin Second Trimester, LMWH From 36 Weeks

This strategy is sometimes used for women with mechanical heart valves, where the thrombotic risk of the prosthetic valve is considered higher than the fetal warfarin risk. Warfarin provides more predictable anticoagulation than LMWH for mechanical valves. The switch to heparin at 36 weeks allows clearance of warfarin before delivery, reducing neonatal hemorrhagic risk.

The Mechanical Heart Valve Dilemma in India

India has a high prevalence of rheumatic heart disease, and many young women of childbearing age have mechanical heart valve prostheses. The anticoagulation management of pregnancy in these women is among the most challenging clinical scenarios, requiring careful risk-benefit discussion. FOGSI recommends a multidisciplinary team approach involving cardiology, obstetrics, hematology, and neonatology. The choice between LMWH-only and warfarin-hybrid strategies should be individualized based on valve type, position, thromboembolic risk, and patient preference after informed consent.

Neonatal Assessment and Management After Anticoagulant Exposure

Warfarin-Exposed Neonates: Emergency Protocol

1. Immediate Vitamin K: Administer Vitamin K1 (phytonadione) 1 mg IM at birth (standard for all neonates, but especially critical for warfarin exposure).
2. Coagulation profile: Check PT, INR, aPTT, and fibrinogen from cord blood or within the first hour. If INR is significantly elevated (above 3), consider fresh frozen plasma (FFP) 10-15 mL/kg.
3. Cranial ultrasound: Perform within 24 hours to rule out intracranial hemorrhage, regardless of clinical signs.
4. Avoid invasive procedures: Minimize heel pricks, avoid circumcision, and use cautious venipuncture technique until coagulation normalizes.
5. Observation period: Monitor for bleeding signs (petechiae, ecchymoses, bloody stools, oozing from cord) for a minimum of 5-7 days.
6. Physical examination: Assess for features of warfarin embryopathy if first-trimester exposure occurred: nasal bridge, limb lengths, skeletal survey if indicated.

Heparin-Exposed Neonates

Neonates exposed to maternal UFH or LMWH require no additional monitoring beyond standard neonatal care, as these drugs do not cross the placenta. Standard Vitamin K prophylaxis at birth applies to all neonates regardless of maternal anticoagulant type.

DOAC-Exposed Neonates (Accidental Exposure)

If accidental DOAC exposure during pregnancy is identified, neonatal assessment should include a coagulation profile, CBC, and clinical monitoring for bleeding. Specific reversal agents (idarucizumab for dabigatran, andexanet alfa for factor Xa inhibitors) have not been studied in neonates, and supportive care with FFP and Vitamin K is the practical approach.

Indian Clinical Context

Rheumatic Heart Disease Prevalence

India has the highest burden of rheumatic heart disease globally, with an estimated 25-30 million affected individuals. Many women of childbearing age have undergone valve replacement with mechanical prostheses, creating a large population requiring pregnancy anticoagulation management. The economic constraints of LMWH cost (INR 300-500 per injection daily for months) versus warfarin (INR 2-5 per day) significantly influence treatment decisions in Indian practice.

FOGSI and Indian Hematology Society Guidelines

Indian guidelines recognize the cost challenges and recommend the following pragmatic approach for mechanical heart valves in pregnancy. First trimester (weeks 6-12): switch to LMWH (or UFH if cost-prohibitive) to avoid embryopathy. Weeks 13-36: warfarin is acceptable with target INR 2.5-3.5 for mitral valves, with informed consent. From 36 weeks: switch to LMWH or IV UFH. For delivery: stop LMWH 24 hours before planned delivery; stop UFH 6 hours before. Postpartum: resume anticoagulation 6-12 hours after delivery.

Breastfeeding and Anticoagulants

Both warfarin and heparins are compatible with breastfeeding. Warfarin is highly protein-bound and does not transfer to breast milk in clinically significant amounts. Heparins are not absorbed orally and pose no risk even if traces enter breast milk. DOACs have limited breastfeeding data and are generally avoided during lactation. This compatibility is important for Indian mothers who may need to resume anticoagulation postpartum while establishing breastfeeding.

Long-Term Follow-Up for Warfarin-Exposed Neonates

Neonates with confirmed first-trimester warfarin exposure require developmental follow-up with particular attention to skeletal development, growth parameters, and neurological assessment if CNS abnormalities were suspected. Skeletal survey at 3-6 months can identify residual chondrodysplasia changes. Audiological assessment is recommended if CNS exposure occurred. HEAMAC neonatal care resources provide structured follow-up pathways for neonates requiring ongoing surveillance after significant maternal drug exposure during pregnancy.

Conclusion: Safe Anticoagulation Strategy for Every Pregnant Woman

Anticoagulation in pregnancy demands meticulous planning, with drug selection guided by the clinical indication, gestational age, and neonatal risk profile. LMWH is the universal safe choice for the fetus and neonate. When warfarin use is unavoidable, restricting it to the second trimester, planning the switch to heparin by 36 weeks, and implementing systematic neonatal hemorrhagic surveillance at delivery are essential safeguards. Indian clinicians face unique challenges with the high prevalence of mechanical heart valves and cost considerations, making individualized, multidisciplinary decision-making critical for optimizing both maternal and neonatal outcomes.